Q-omics provides the consensus-scored KCNQ1 profile across patient tissues and cancer cell-line models. KCNQ1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, KCNQ1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, KCNQ1 RNA expression shows 19,030 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight STAD, KIRC, and LSCC as cancer lineages where KCNQ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNQ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNQ1 survival associations across molecular data types. KCNQ1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNQ1 RNA expression–survival associations across cancer types. High KCNQ1 expression shows unfavorable associations in LUSC and LAML, but favorable associations in STAD, KIRC, SKCM and READ. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for KCNQ1 RNA expression.
This table summarizes KCNQ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KCNQ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNQ1 shows lower tumor expression in KIRC, KIRP, THCA, LUAD and LUSC and higher tumor expression in COAD. The KIRC box plot shows higher KCNQ1 RNA expression in normal versus tumor tissue (log2 FC = −2.123, t-test p < 0.001).
This table shows molecular features associated with KCNQ1 in patient tissues and cancer cell lines. In patient samples, KCNQ1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNQ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
